ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells

Por Nadkarni, Aditi, Shrivastav, Meena, Mladek, Ann C., Schwingler, Paul M., Grogan, Patrick T., Chen, Junjie, Sarkaria, Jann N.
Publicado em 2012

Disruption of Parallel and Converging Signaling Pathways Contributes to the Synergistic Antitumor Effects of Simultaneous mTOR and EGFR Inhibition in GBM Cells

Por Rao, Ravi D, Mladek, Ann C, Lamont, Jeffrey D, Goble, Jennie M, Erlichman, Charles, James, C David, Sarkaria, Jann N
Publicado em 2005

INFLUENCE OF DRUG DELIVERY ON THERAPEUTIC BENEFIT IN GBM–CDK4 AND MDM2 INHIBITOR COMPARISON IN FLANK VERSUS ORTHOTOPIC MODELS AND COMPARISON OF BRAIN PENETRANT VERSUS IMPENETRANT P...

Por Sarkaria, Jann N., Pokorny, Jenny L., Mladek, Ann C., Parrish, Karen, Oberoi, Rajneet, Sio, Terence, Mittapalli, Rajendar K., Elmquist, William F.
Publicado em 2014

Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth

Por Ramirez, Yulian P., Mladek, Ann C., Phillips, Roger M., Gynther, Mikko, Rautio, Jarkko, Ross, Alonzo H., Wheelhouse, Richard T., Sakaria, Jann N.
Publicado no Mol Cancer Ther (2014)

Discordant in vitro and in vivo chemo-potentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts

Por Gupta, Shiv K., Mladek, Ann C., Carlson, Brett L., Boakye-Agyeman, Felix, Bakken, Katrina, Kizilbash, Sani, Schroeder, Mark A., Reid, Joel, Sarkaria, Jann N.
Publicado em 2014

USING FLUORODEOXYTHYMIDINE TO MONITOR ANTI-EGFR INHIBITOR THERAPY IN SQUAMOUS CELL CARCINOMA XENOGRAFTS

Por Atkinson, David M., Clarke, Michelle J., Mladek, Ann C., Carlson, Brett L., Trump, David P., Jacobson, Mark S., Kemp, Brad J., Lowe, Val J., Sarkaria, Jann N.
Publicado em 2008

Radiosensitizing effects of TMZ observed in vivo only in a subset of MGMT methylated GBM xenografts

Por Carlson, Brett L., Grogan, Patrick T., Mladek, Ann C., Schroeder, Mark A., Kitange, Gaspar J., Decker, Paul A., Giannini, Caterina, Wu, Wenting, Ballman, Karla A., James, C. David, Sarkaria, Jann N.
Publicado em 2009

Effective sensitization of temozolomide by ABT-888 is lost with development of TMZ resistance in glioblastoma xenograft lines

Por Clarke, Michelle J., Mulligan, Evan A., Grogan, Patrick T., Mladek, Ann C., Carlson, Brett L., Schroeder, Mark A., Curtin, Nicola J., Lou, Zhenkun, Decker, Paul A., Wu, Wenting, Plummer, E. Ruth, Sarkaria, Jann N.
Publicado em 2009

Evaluation of MGMT Promoter Methylation Status and Correlation with Temozolomide Response in Orthotopic Glioblastoma Xenograft Model

Por Kitange, Gaspar J., Carlson, Brett L., Mladek, Ann C., Decker, Paul A., Schroeder, Mark A., Wu, Wenting, Grogan, Patrick T., Giannini, Caterina, Ballman, Karla V., Buckner, Jan C., James, C. David, Sarkaria, Jann N.
Publicado em 2008

Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins

Por Kitange, Gaspar J., Mladek, Ann C., Schroeder, Mark A., Pokorny, Jenny C., Carlson, Brett L., Zhang, Yuji, Nair, Asha A., Lee, Jeong-Heon, Yan, Huihuang, Decker, Paul A., Zhang, Zhiguo, Sarkaria, Jann N.
Publicado no Cell Rep (2016)

Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models

Por Cen, Ling, Carlson, Brett L., Pokorny, Jenny L., Mladek, Ann C., Grogan, Patrick T., Schroeder, Mark A., Decker, Paul A., Anderson, S. Keith, Giannini, Caterina, Wu, Wenting, Ballman, Karla V., Kitange, Gaspar J., Sarkaria, Jann N.
Publicado em 2013

Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts()

Por Kitange, Gaspar J., Mladek, Ann C., Carlson, Brett L., Schroeder, Mark A., Pokorny, Jenny L., Cen, Ling, Decker, Paul A., Wu, Wenting, Lomberk, Gwen A., Gupta, Shiv K., Urrutia, Raul A., Sarkaria, Jann N.
Publicado em 2012

p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells

Por Cen, Ling, Carlson, Brett L., Schroeder, Mark A., Ostrem, Jamie L., Kitange, Gaspar J., Mladek, Ann C., Fink, Stephanie R., Decker, Paul A., Wu, Wenting, Kim, Jung-Sik, Waldman, Todd, Jenkins, Robert B., Sarkaria, Jann N.
Publicado em 2012

PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel

Por Yang, Lin, Clarke, Michelle J., Carlson, Brett L., Mladek, Ann C., Schroeder, Mark A., Decker, Paul, Wu, Wenting, Kitange, Gaspar J., Grogan, Patrick T., Goble, Jennie M., Uhm, Joon, Galanis, Evanthia, Giannini, Caterina, Lane, Heidi A., James, C. David, Sarkaria, Jann N.
Publicado em 2008

Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma

Por Gupta, Shiv K., Kizilbash, Sani H., Carlson, Brett L., Mladek, Ann C., Boakye-Agyeman, Felix, Bakken, Katrina K., Pokorny, Jenny L., Schroeder, Mark A., Decker, Paul A., Cen, Ling, Eckel-Passow, Jeanette E., Sarkar, Gobinda, Ballman, Karla V., Reid, Joel M., Jenkins, Robert B., Verhaak, Roeland G., Sulman, Erik P., Kitange, Gaspar J., Sarkaria, Jann N.
Publicado no J Natl Cancer Inst (2015)